Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 0.64 |
| ▸ | GSK3B | P49841 | 13/20 | 0.64 |
| ▸ | WNT1 | P04628 | 12/20 | 0.62 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | CLK3 | P49761 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19546571 | 0.90 | DYRK1A (0.51) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916418 | 0.86 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048782 | 0.85 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048851 | 0.82 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916457 | 0.82 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916481 | 0.82 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048929 | 0.82 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048932 | 0.81 | DYRK1A (0.66) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048621 | 0.81 | DYRK1A (0.64) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916374 | 0.81 | DYRK1A (0.64) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3448386-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED LLC (US) | 2021-03-03 | — | — | EP | disclosed |